Article
Medicine, General & Internal
Deok-Gie Kim, Shin Hwang, Jong Man Kim, Je Ho Ryu, Young Kyoung You, Donglak Choi, Bong-Wan Kim, Dong-Sik Kim, Yang Won Nah, Tae-Seok Kim, Jai Young Cho, Geun Hong, Jae Do Yang, Jaryung Han, Suk-Won Suh, Kwan Woo Kim, Yun Kyung Jung, Ju Ik Moon, Jun Young Lee, Sung Hwa Kim, Jae Geun Lee, Myoung Soo Kim, Kwang-Woong Lee, Dong Jin Joo
Summary: This study identified pre- and post-transplant non-renal risk factors for chronic kidney disease (CKD) following liver transplants. Age, gender, body mass index, pre-transplant diabetes, and performance status were found to be baseline risk factors for CKD. Recurrent hepatocellular carcinoma and infection were identified as significant post-transplant risk factors for CKD.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Pharmacology & Pharmacy
Lekshmy Srinivas, Noble Gracious, Radhakrishnan R. Nair
Summary: Tacrolimus is an immunosuppressant used in solid organ transplantation. This study in South Indian renal transplant recipients investigated the effects of gene polymorphisms on tacrolimus concentrations and adverse effects. The findings suggest that genotype-guided initial dosing of tacrolimus can help achieve optimal drug levels and prevent adverse effects.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Yilei Yang, Xin Huang, Yinping Shi, Rui Yang, Haiyan Shi, Xinmei Yang, Guoxiang Hao, Yi Zheng, Jianning Wang, Lequn Su, Yan Li, Wei Zhao
Summary: A CYP3A5 genotype-dependent drug-drug interaction was found between tacrolimus and nifedipine in Chinese renal transplant patients. Personalized therapy accounting for CYP3A5 genotype detection and therapeutic drug monitoring is necessary for these patients receiving tacrolimus and nifedipine treatment.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Medicine, Research & Experimental
Milosz Miedziaszczyk, Ilona Idasiak-Piechocka
Summary: Tacrolimus and omeprazole are commonly used drugs in kidney transplant patients. However, simultaneous administration may lead to drug interactions, affecting the pharmacokinetics of tacrolimus and potentially causing adverse reactions. It is important to address these interactions and find appropriate solutions.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Medicine, General & Internal
Deok Gie Kim, Sung Hwa Kim, Shin Hwang, Suk Kyun Hong, Je Ho Ryu, Bong-Wan Kim, Young Kyoung You, Donglak Choi, Dong-Sik Kim, Yang Won Nah, Jai Young Cho, Tae-Seok Kim, Geun Hong, Dong Jin Joo, Myoung Soo Kim, Jong Man Kim, Jae Geun Lee
Summary: Tacrolimus monotherapy is considered a viable option for early post-liver transplantation, but its effects in the recent era of reduced tacrolimus and mycophenolate mofetil remain unclear. This study compared the outcomes of liver recipients who received tacrolimus monotherapy or continued tacrolimus/mycophenolate mofetil therapy within 12 months after transplantation. The results showed similar rates of rejection and graft failure between the two groups, but a greater decline in renal function and higher required tacrolimus dose in the monotherapy group.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Xiaoying He, Xi Yang, Xiaoting Yan, Mingzhu Huang, Zheng Xiang, Yan Lou
Summary: The study found that T lymphocytes' pharmacodynamic response to tacrolimus was closely related to renal function and the prognosis of renal transplant patients. Metabolomic analysis identified potential biomarkers that could predict the efficacy of tacrolimus. Pathway and logistic regression analysis revealed the mechanism of individual variation and provided a basis for personalized drug therapy.
Article
Biochemistry & Molecular Biology
Asmae Belhaj, Laurence Dewachter, Astrid Monier, Gregory Vegh, Sandrine Rorive, Myriam Remmelink, Melanie Closset, Christian Melot, Jacques Creteur, Isabelle Salmon, Benoit Rondelet
Summary: Tacrolimus can prevent right ventricular dysfunction caused by brain death by inhibiting apoptosis and inflammation activation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Health Care Sciences & Services
Remi Lenain, Mehdi Maanaoui, Aghiles Hamroun, Romain Larrue, Cynthia Van Der Hauwaert, Jean-Baptiste Gibier, Viviane Gnemmi, Sebastien Gomis, Myriam Labalette, Franck Broly, Benjamin Hennart, Nicolas Pottier, Marc Hazzan, Christelle Cauffiez, Francois Glowacki
Summary: The study found that implementing a tacrolimus capping strategy in CYP3A5*1/- recipients is associated with improved glomerular filtration rate without a significant increase in biopsy-proven acute rejection incidence.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Oncology
Yiyang Li, Huimin An, Chuan Shen, Boqian Wang, Ting Zhang, Yifan Hong, Hui Jiang, Peijun Zhou, Xianting Ding
Summary: FK506 and RAPA have different effects on T-cell lineages after transplantation, leading to different immune responses and transplant outcomes. Long-term RAPA treatment can reduce the occurrence of tumors and infections.
CLINICAL AND TRANSLATIONAL MEDICINE
(2021)
Article
Biology
Dagmara Szypulska-Koziarska, Aleksandra Wilk, Malgorzata Marchelek-Mysliwiec, Daria Sleboda-Taront, Barbara Wiszniewska
Summary: Renal transplant recipients need lifelong immunosuppressive therapy, which can affect the hormonal balance of sex hormones in both men and women. A tacrolimus-based immunosuppressive regimen may lead to hormonal imbalance that influences fertility, so careful consideration is needed when choosing the treatment plan for reproductive-age recipients.
Article
Biochemistry & Molecular Biology
Nadia Meyer, Lars Brodowski, Constantin von Kaisenberg, Bianca Schroeder-Heurich, Frauke Von Versen-Hoeynck
Summary: This study investigated the effects of CsA and Tac on endothelial colony-forming cells (ECFCs), finding that these immunosuppressants not only impair vascular repair and angiogenesis, but also trigger an inflammatory cascade and increase cardiovascular risk in transplant patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Pharmacology & Pharmacy
Pere Fontova, Lisanne N. van Merendonk, Anna Vidal-Alabro, Raul Rigo-Bonnin, Gema Cerezo, Stefaan van Oevelen, Oriol Bestard, Edoardo Melilli, Nuria Montero, Ana Coloma, Anna Manonelles, Joan Torras, Josep M. Cruzado, Josep M. Grinyo, Helena Colom, Nuria Lloberas
Summary: Despite monitoring whole blood tacrolimus concentrations, acute rejection can still occur during tacrolimus therapy after kidney transplantation. This study aimed to investigate the intracellular pharmacokinetics (PK) of two tacrolimus formulations (immediate-release and extended-release) and their correlation with whole blood PK and pharmacodynamics (PD).
Article
Immunology
Yuan Liu, Rui Wang, Peizhen Wen, Wenbin An, Jinxin Zheng, Tao Zhang, Pengshan Zhang, Haoyu Wang, Fan Zou, Hui Pan, Junwei Fan, Zhihai Peng
Summary: This study investigated the genetic risk of patients with tacrolimus intolerance after liver transplantation. The results suggested that switching to cyclosporine (SFTC) may increase the risk of dyslipidemia and insulin resistance, while specific SNPs of CYP3A5 gene could be potential genetic risks for tacrolimus intolerance.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Estefani Yaquelin Hernandez-Cruz, Isabel Amador-Martinez, Ana Karina Aranda-Rivera, Alfredo Cruz-Gregorio, Jose Pedraza Chaverri
Summary: Cadmium (Cd) is a toxic metal that can accumulate in living organisms, especially in the kidney. The mitochondria play a crucial role in Cd-induced kidney damage, leading to chronic kidney disease. Current therapies for Cd nephrotoxicity have limitations, and there is a need for new treatment approaches. Mitochondrial transplantation has shown promising results in reversing mitochondrial alterations caused by oxidative stress, and it is proposed as a novel therapy for Cd-induced kidney damage.
CHEMICO-BIOLOGICAL INTERACTIONS
(2022)
Article
Pharmacology & Pharmacy
Benedetta C. Sallustio, Benjamin D. Noll, Rong Hu, Daniel T. Barratt, Jonathan Tuke, Janet K. Coller, Graeme R. Russ, Andrew A. Somogyi
Summary: Recipient and donor CYP3A5 and ABCB1 3435C>T genotypes do not determine allograft tacrolimus exposure in kidney transplant recipients. However, tacrolimus dose and C-0Blood are significant predictors of C-Graft, and the relationship between C-0Blood and C-Graft appears to differ in the presence or absence of acute nephrotoxicity.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2021)
Article
Pediatrics
Karlijn J. van Stralen, Joyce E. van Tol, Saskia N. de Wildt, Matthijs L. Becker, Marlies A. van Houten
Summary: This Dutch study evaluated the safety of xylometazoline spray or drops for nasal decongestion in infants under 2 years of age and concluded that they appear to be safe. The study found that the use of low-dose xylometazoline in hospitalized infants was associated with a lower incidence of side effects compared to saline-only treatment. The results suggest that xylometazoline can be effective and safe in facilitating breathing and drinking in infants with nasal congestion.
ARCHIVES OF DISEASE IN CHILDHOOD
(2023)
Article
Nanoscience & Nanotechnology
Liang Wu, Wouter W. Woud, Carla C. Baan, Dennis A. Hesselink, Edwin van der Pol, Guido Jenster, Karin Boer
Summary: This study demonstrates the detection of single urinary extracellular vesicles (uEVs) without isolation using imaging flow cytometry (IFCM). A gate was defined to distinguish uEVs from auto-fluorescent particles, and the final readouts were verified as single EVs. This isolation-free protocol provides a method to quantify and phenotype single uEVs, eliminating the influence of auto-fluorescent particles and protein aggregates.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
(2023)
Article
Pediatrics
Marika A. de Hoop-Sommen, Tjitske M. van der Zanden, Karel Allegaert, Robert B. Flint, Sinno H. P. Simons, Saskia N. de Wildt
Summary: The NeoDose project aimed to develop best evidence dosing recommendations for term and preterm neonates. Through a three-step approach, drug selection, consensus-based DR establishment, and evidence-based DR establishment, a total of 37 best evidence dosing recommendations were established for neonates.
Article
Immunology
Hilal Varol, Angela Ernst, Iacopo Cristoferi, Wolfgang Arns, Carla C. Baan, Myrthe van Baardwijk, Thierry van den Bosch, Jennifer Eckhoff, Ana Harth, Dennis A. Hesselink, Folkert J. van Kemenade, Willem de Koning, Christine Kurschat, Robert C. Minnee, Dana A. Mustafa, Marlies E. J. Reinders, Shazia P. Shahzad-Arshad, Malou L. H. Snijders, Dirk Stippel, Andrew P. Stubbs, Jan von der Thusen, Katharina Wirths, Jan U. Becker, Marian C. Clahsen-van Groningen
Summary: This study assessed the feasibility and potential of using NanoString nCounter analysis on KTx biopsies to aid in the classification of rejection in clinical practice. The results showed that transcriptome analysis has the potential to differentiate between different types of kidney transplant rejection and could be valuable in assisting with the classification of kidney transplant rejection.
Article
Peripheral Vascular Disease
Laura E. J. Peeters, Dennis. A. Hesselink, Melvin Lafeber, David Severs, Martijn W. F. van den Hoogen, Michelle A. H. Sonneveld, Christian R. B. Ramakers, Soma Bahmany, Teun van Gelder, Birgit C. P. Koch, Jorie Versmissen
Summary: The study aimed to determine the prevalence of nonadherence to antihypertensive drugs (AHDs) among patients visiting the nephrology and vascular outpatient clinics. Adherence was assessed by measuring drug concentrations in blood, and the overall adherence rate to AHDs was 78.2%. Furthermore, patients after kidney transplant had a higher adherence rate of 85.7%.
JOURNAL OF HYPERTENSION
(2023)
Correction
Pediatrics
Athimalaipet Ramanan, Neena Modi, Saskia de Wildt
PEDIATRIC RESEARCH
(2023)
Review
Immunology
G. van der Elst, H. Varol, M. Hermans, C. C. Baan, J. P. Duong-van Huyen, D. A. Hesselink, R. Kramann, M. Rabant, M. E. J. Reinders, J. H. von der Thuesen, T. P. P. van den Bosch, M. C. Clahsen-van Groningen
Summary: Mast cells are innate immune cells that play multiple roles in immune responses. In addition to their involvement in allergies, they also participate in allograft tolerance and rejection by interacting with regulatory T cells, effector T cells, and B cells, and releasing cytokines and other mediators. Mast cell mediators have both pro- and anti-inflammatory actions, but they overall favor pro-fibrotic pathways. Interestingly, they are also considered to have potential protective effects in tissue remodeling post-injury. This manuscript provides an in-depth understanding of the functional diversity of mast cells in kidney transplants, proposing a model that highlights their dual protective and harmful capabilities in this setting.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Pharmacology & Pharmacy
Tom G. Jacobs, Marika A. de Hoop-Sommen, Thomas Nieuwenstein, Joyce E. M. van der Heijden, Saskia N. de Wildt, David M. Burger, Angela Colbers, Jolien J. M. Freriksen
Summary: Dose recommendations for lamivudine or emtricitabine in children with HIV and CKD are lacking. Physiologically based pharmacokinetic models were used to develop dosing strategies for these drugs in this population. The models were successfully verified and the simulations showed that GFR-adjusted dosages resulted in adequate drug exposure in children with CKD. Clinical studies are needed to confirm these findings.
Editorial Material
Pediatrics
Saskia N. de Wildt, Ivan Foeldvari, Angeliki Siapkara, Pirkko Lepola, Berit Kristroem, Lucia Ruggieri, Irmgard Eichler, Gunter F. Egger
LANCET CHILD & ADOLESCENT HEALTH
(2023)
Article
Transplantation
Hilal Varol, Guus van der Elst, Carla C. Baan, Myrthe van Baardwijk, Dennis A. Hesselink, Jean-Paul Duong van Huyen, Rafael Kramann, Marion Rabant, Thierry P. P. van den Bosch, Marian C. Clahsen-van Groningen
Summary: This study investigated the potential contribution of mast cells (MCs) to minimal inflammatory lesions in kidney transplants (KTx). The results showed that MC number was correlated with post-transplantation time and interstitial fibrosis, but not with transplant function or survival.
TRANSPLANTATION DIRECT
(2023)
Article
Transplantation
Aleixandra Mendoza Rojas, Jeroen G. H. P. Verhoeven, Ronella de Kuiper, Marian C. Clahsen-van Groningen, Karin Boer, Dennis A. Hesselink, Teun van Gelder, Nicole M. van Besouw, Carla C. Baan
Summary: This study validates that a high number of donor-reactive memory T cells before transplantation is associated with the development of acute rejection after transplantation. Furthermore, it demonstrates that the IFN-gamma and IL-21 ELISPOT assays are able to discriminate between patients with acute rejection and patients without acute rejection at the time of biopsy sampling.
TRANSPLANTATION DIRECT
(2023)
Editorial Material
Immunology
Carla C. Baan, Marlies E. J. Reinders, Dennis A. Hesselink
Article
Medicine, Research & Experimental
Daphne M. Hullegie-Peelen, Hector Tejeda Mora, Dennis A. Hesselink, Eric M. J. Bindels, Thierry P. P. van den Bosch, Marian C. Clahsen-van Groningen, Marjolein Dieterich, Sebastiaan Heidt, Robert C. Minnee, Georges M. G. M. Verjans, Martin J. Hoogduijn, Carla C. Baan
Summary: This study demonstrates the presence of diverse populations of tissue-resident lymphocytes (TRLs) in kidney transplants, including innate, innate-like, and adaptive TRLs. Chimerism of donor and recipient cells is common in kidney transplants and is present in all types of tissue-resident memory T cells. These cells may contribute to local protection against viral pathogens.
Meeting Abstract
Peripheral Vascular Disease
Laura E. J. Peeters, Dennis A. Hesselink, Brenda C. M. de Winter, Melvin Lafeber, David Severs, Martijn W. F. van den Hoogen, Michelle A. H. Sonneveld, Chris R. B. Ramakers, Soma Bahmany, Teun van Gelder, Birgit C. P. Koch, Jorie Versmissen
JOURNAL OF HYPERTENSION
(2023)
Article
Surgery
Lukas K. van Vugt, Marieke van der Zwan, Marian C. Clahsen-van Groningen, Madelon van Agteren, Daphne M. Hullegie-Peelen, Brenda C. M. De Winter, Marlies E. J. Reinders, Pedro Miranda Afonso, Dennis A. Hesselink
Summary: Alemtuzumab is an effective treatment for severe kidney transplant rejection, but it results in long-lasting lymphocyte depletion and is associated with frequent infections and worse patient survival outcomes.
TRANSPLANT INTERNATIONAL
(2023)